![logo](/logos/ONCT.webp)
Oncternal Therapeutics, Inc.
NASDAQ:ONCT
7.09 (USD) • At close July 26, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Oncternal Therapeutics, Inc. |
Symbool | ONCT |
Munteenheid | USD |
Prijs | 7.09 |
Beurswaarde | 20,983,919 |
Dividendpercentage | 0% |
52-weken bereik | 5.57 - 13.2 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. James B. Breitmeyer M.D., Ph.D. |
Website | https://www.oncternal.com |
An error occurred while fetching data.
Over Oncternal Therapeutics, Inc.
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)